E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent

Exclusion Criteria

• •Women with known pregnancy or who are lactating.
• •Patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, drugs such as ABT-578, rapamycin, tacrolimus, sirolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media.
• •Patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated.
• •Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.
• •Current medical condition with a life expectancy of less than 12 months.
• •The subject is participating in another device or drug study. Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. The subject may only be enrolled in this E-five registry once.
• •Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this registry.